Cargando…

24-Month Outcomes of Ahmed ClearPath(®) Glaucoma Drainage Device for Refractory Glaucoma

PURPOSE: To describe the safety and efficacy of the Ahmed ClearPath(®) (ACP) 250 mm(2) glaucoma drainage device (GDD) in the treatment of refractory primary open-angle glaucoma (POAG). PATIENTS AND METHODS: This was a retrospective, noncomparative, single-surgeon, interventional case series of adult...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorairaj, Syril, Checo, Leticia A, Wagner, Isabella V, Ten Hulzen, Richard D, Ahuja, Abhimanyu S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289452/
https://www.ncbi.nlm.nih.gov/pubmed/35859670
http://dx.doi.org/10.2147/OPTH.S368634
_version_ 1784748669066543104
author Dorairaj, Syril
Checo, Leticia A
Wagner, Isabella V
Ten Hulzen, Richard D
Ahuja, Abhimanyu S
author_facet Dorairaj, Syril
Checo, Leticia A
Wagner, Isabella V
Ten Hulzen, Richard D
Ahuja, Abhimanyu S
author_sort Dorairaj, Syril
collection PubMed
description PURPOSE: To describe the safety and efficacy of the Ahmed ClearPath(®) (ACP) 250 mm(2) glaucoma drainage device (GDD) in the treatment of refractory primary open-angle glaucoma (POAG). PATIENTS AND METHODS: This was a retrospective, noncomparative, single-surgeon, interventional case series of adult patients with medically ± surgically refractory POAG undergoing ACP implantation. Intraocular pressure (IOP), the number of glaucoma medications, and complications were recorded over 24 months of follow-up. Primary outcomes included mean reductions in both IOP and medication use through 24 months, and secondary outcomes included the proportion of eyes achieving an IOP between 6 and 19 mmHg, IOP reduction by ≥20%, and reduction by ≥1 medication at last mean follow-up. RESULTS: Twelve eyes of 11 patients (mean age 71.3 ± 14.1 years) fit inclusion criteria and were enrolled. Most patients were Caucasian (n = 8), female (n = 10), and all had severe POAG (n = 11). The mean last follow-up was 18 months, at which time the mean (standard deviation) baseline IOP of 29.0 (7.6) mmHg was reduced to 12.2 (4.0) mmHg (58% reduction). 91.7% of eyes achieved an IOP between 6 and 19 mmHg, and 100% of eyes met an IOP reduction of ≥20%. Mean baseline number of glaucoma medications was 3.0 (0.9) and was reduced to 0.5 (0.7) at last mean follow-up (83.3% reduction), with 91.7% of eyes using ≥1 fewer medications. No long-term complications were observed, and short-term complications (mild hyphema, inflammation, and pain) were resolved by month 3. CONCLUSION: To our knowledge, this is the second long-term study evaluating the efficacy of the Ahmed ClearPath drainage device in adult patients, and the first study with 24-months follow-up. The ACP device is safe and effective at reducing both IOP and medication burdens in patients with severe POAG. Additionally, minimal short-term complications were noted with no long-term adverse effects, increasing comfort for both the surgeon and the patient.
format Online
Article
Text
id pubmed-9289452
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92894522022-07-19 24-Month Outcomes of Ahmed ClearPath(®) Glaucoma Drainage Device for Refractory Glaucoma Dorairaj, Syril Checo, Leticia A Wagner, Isabella V Ten Hulzen, Richard D Ahuja, Abhimanyu S Clin Ophthalmol Original Research PURPOSE: To describe the safety and efficacy of the Ahmed ClearPath(®) (ACP) 250 mm(2) glaucoma drainage device (GDD) in the treatment of refractory primary open-angle glaucoma (POAG). PATIENTS AND METHODS: This was a retrospective, noncomparative, single-surgeon, interventional case series of adult patients with medically ± surgically refractory POAG undergoing ACP implantation. Intraocular pressure (IOP), the number of glaucoma medications, and complications were recorded over 24 months of follow-up. Primary outcomes included mean reductions in both IOP and medication use through 24 months, and secondary outcomes included the proportion of eyes achieving an IOP between 6 and 19 mmHg, IOP reduction by ≥20%, and reduction by ≥1 medication at last mean follow-up. RESULTS: Twelve eyes of 11 patients (mean age 71.3 ± 14.1 years) fit inclusion criteria and were enrolled. Most patients were Caucasian (n = 8), female (n = 10), and all had severe POAG (n = 11). The mean last follow-up was 18 months, at which time the mean (standard deviation) baseline IOP of 29.0 (7.6) mmHg was reduced to 12.2 (4.0) mmHg (58% reduction). 91.7% of eyes achieved an IOP between 6 and 19 mmHg, and 100% of eyes met an IOP reduction of ≥20%. Mean baseline number of glaucoma medications was 3.0 (0.9) and was reduced to 0.5 (0.7) at last mean follow-up (83.3% reduction), with 91.7% of eyes using ≥1 fewer medications. No long-term complications were observed, and short-term complications (mild hyphema, inflammation, and pain) were resolved by month 3. CONCLUSION: To our knowledge, this is the second long-term study evaluating the efficacy of the Ahmed ClearPath drainage device in adult patients, and the first study with 24-months follow-up. The ACP device is safe and effective at reducing both IOP and medication burdens in patients with severe POAG. Additionally, minimal short-term complications were noted with no long-term adverse effects, increasing comfort for both the surgeon and the patient. Dove 2022-07-13 /pmc/articles/PMC9289452/ /pubmed/35859670 http://dx.doi.org/10.2147/OPTH.S368634 Text en © 2022 Dorairaj et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Dorairaj, Syril
Checo, Leticia A
Wagner, Isabella V
Ten Hulzen, Richard D
Ahuja, Abhimanyu S
24-Month Outcomes of Ahmed ClearPath(®) Glaucoma Drainage Device for Refractory Glaucoma
title 24-Month Outcomes of Ahmed ClearPath(®) Glaucoma Drainage Device for Refractory Glaucoma
title_full 24-Month Outcomes of Ahmed ClearPath(®) Glaucoma Drainage Device for Refractory Glaucoma
title_fullStr 24-Month Outcomes of Ahmed ClearPath(®) Glaucoma Drainage Device for Refractory Glaucoma
title_full_unstemmed 24-Month Outcomes of Ahmed ClearPath(®) Glaucoma Drainage Device for Refractory Glaucoma
title_short 24-Month Outcomes of Ahmed ClearPath(®) Glaucoma Drainage Device for Refractory Glaucoma
title_sort 24-month outcomes of ahmed clearpath(®) glaucoma drainage device for refractory glaucoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289452/
https://www.ncbi.nlm.nih.gov/pubmed/35859670
http://dx.doi.org/10.2147/OPTH.S368634
work_keys_str_mv AT dorairajsyril 24monthoutcomesofahmedclearpathglaucomadrainagedeviceforrefractoryglaucoma
AT checoleticiaa 24monthoutcomesofahmedclearpathglaucomadrainagedeviceforrefractoryglaucoma
AT wagnerisabellav 24monthoutcomesofahmedclearpathglaucomadrainagedeviceforrefractoryglaucoma
AT tenhulzenrichardd 24monthoutcomesofahmedclearpathglaucomadrainagedeviceforrefractoryglaucoma
AT ahujaabhimanyus 24monthoutcomesofahmedclearpathglaucomadrainagedeviceforrefractoryglaucoma